News & Events

Stamford announces positive results from Phase 2 Study of SP-002 in combination with 4-weeks of vismodegib in multi-lesional Basal Cell Carcinoma patients

January 17, 2025

Stamford has announced positive results for its ASN-002-003 multi-lesional clinical trial (NCT 04416516. Protocol No ASN-002-003) evaluating SP-002, an Adenovirus-5...

Stamford Pharmaceuticals Inc announces the first patient to be treated with SP-002 in combination with Erivedge® in a Phase 2 Study in locally advanced BCC subjects

April 10, 2024

Stamford Pharmaceuticals Inc, a clinical-stage biotechnology company developing science-driven immune therapies, today announced initiation of its locally advanced basal cell...

Stamford Expands its Scientific Advisory Team

April 1, 2024

Stamford Pharmaceuticals Inc., a clinical-stage biotechnology company developing science-driven immune therapies, focused on cutaneous and visceral cancers, today announced that...

Stamford Pharmaceuticals Inc announces Dr Jacques Banchereau at Chief Scientific Officer

October 1, 2023

Stamford Pharmaceuticals Inc., a clinical-stage biotechnology company developing science-driven immune therapies focused on cutaneous and visceral cancers, today announced the...

Stamford Pharmaceuticals Inc has relocated its head office to Austin Texas

May 8, 2023

Stamford Pharmaceuticals Inc, a clinical stage oncology company with a near-term pipeline focused on cutaneous cancer announced today that it...

Stamford Pharmaceuticals Inc announces amendment and expansion of the ASN-002-003 Phase 2a Study in BCNS and sporadic BCC subjects with up to an addition 5 arms

April 14, 2023

Stamford Pharmaceuticals Inc, today announced the expansion of its ASN-002-003 Phase 2A study (NCT 04416516). The study performed in collaboration...